NewAmsterdam Pharma N.V. Financial Statements
NASDAQ: NAMSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
NewAmsterdam Pharma N.V. revenue and earnings
In fiscal 2025, NewAmsterdam Pharma N.V. generated $22.5 million in revenue, down 50.6% from fiscal 2024, its first annual decline since 2023. NewAmsterdam Pharma N.V. reported a net loss of $203.8 million, compared with a loss of $241.6 million a year earlier. Operating margin was -1002.9%.
Diluted earnings per share came in at -$1.72.
Summary generated from market data by MetaCap's automated system. Methodology
NewAmsterdam Pharma N.V. income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 |
|---|---|---|---|---|---|
| Revenue | 22.50M | 45.56M | 14.09M | 102.69M | — |
| Revenue growth (YoY) | -50.61% | +223.37% | -86.28% | — | — |
| Operating Expenses | 248.19M | 221.85M | 197.06M | 106.25M | 34.98M |
| Research & Development | 141.83M | 151.41M | 159.42M | 86.74M | 28.97M |
| Selling, General & Admin | 106.35M | 70.45M | 37.63M | 19.51M | 6.00M |
| Operating Income | -225.68M | -176.29M | -182.97M | -3.56M | -34.98M |
| Interest Expense | — | — | — | 287.00K | 411.00K |
| Pretax Income | -203.82M | -241.60M | -176.91M | -22.63M | -41.78M |
| Income Tax | — | -1.00K | 27.00K | — | — |
| Net Income | -203.82M | -241.60M | -176.94M | -22.63M | -41.78M |
| Net Income growth (YoY) | — | — | — | — | — |
| EPS (Basic) | -1.72 | -2.56 | -2.15 | -1.19 | -3.81 |
| EPS (Diluted) | -1.72 | -2.56 | -2.15 | -1.19 | -3.81 |
| Shares Outstanding (Basic) | 118.42M | 94.36M | 82.16M | 18.97M | 10.98M |
| Shares Outstanding (Diluted) | 118.42M | 94.36M | 82.16M | 18.97M | 10.98M |
| EBITDA | -225.46M | -176.18M | -182.92M | -3.55M | -34.97M |
| Operating Margin | -1002.90% | -386.91% | -1298.56% | -3.46% | — |
| Net Margin | -905.74% | -530.25% | -1255.76% | -22.04% | — |
This table shows 5 annual periods of NewAmsterdam Pharma N.V.'s income statement, from FY 2025 back to FY 2021, across 16 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow NAMS's reporting calendar. What is a income statement?